[Clinical usefulness of serum CYFRA21-1 in colorectal cancer].
Serum CYFRA21-1 levels were studied in 127 cases of colorectal cancer. The positive rates for serum CYFRA21-1 were 34.6% in primary colorectal cancer. There was a significant correlation between the positive rates of serum CYFRA21-1 and liver metastases, peritoneal dissemination, lymph node metastases, or clinical stage. The survival rate for patients in the CYFRA21-1 positive group was lower than those with CYFRA21-1 negative group. Among patients who underwent curative operation, patients is the CYFRA21-1 positive group gave a recurrence rate of 26.6%, against 9.4% in the CYFRA21-1 negative group. There was no correlation between serum CYFRA21-1 levels and serum CEA levels. These findings suggest that Serum CYFRA21-1 levels may be a useful indicator in estimating the prognosis for colorectal cancer.
Miyashita
T
T
Dept. of Surgery II, School of Medicine, Kanazawa University.
Nishimura
G
G
Michiwa
Y
Y
Sato
T
T
Tsugawa
K
K
Fushida
S
S
Sugiyama
K
K
Fujimura
T
T
Yonemura
Y
Y
Miwa
K
K
Miyazaki
I
I
D000230:Adenocarcinoma / Q000175:diagnosis / Q000556:secondary; D000911:Antibodies, Monoclonal / Q000276:immunology; D014408:Biomarkers, Tumor / Q000097:blood*; D003110:Colonic Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology; D006801:Humans; D007633:Keratins / Q000276:immunology*; D008113:Liver Neoplasms / Q000556:secondary; D008207:Lymphatic Metastasis; D009361:Neoplasm Invasiveness; D011379:Prognosis; D012004:Rectal Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology; D015996:Survival Rate
D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; D007633:Keratins